Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab

Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab

Purpose: To evaluate the acute changes in intraocular cytokines after intravitreal bevacizumab (IVB) in proliferative diabetic retinopathy.

Design: Prospective, open-label, controlled, randomized interventional clinical trial.

Participants: Twenty eyes of 28 consecutive patients who are scheduled for pars plana vitrectomy (ppV) for proliferative diabetic retinopathy were prospectively enrolled.

Methods: All patients were randomly assigned to receive IVB either at 2 or 7 days before ppV. Aqueous humor samples were taken from anterior chamber just before IVB and at the time of surgery. Multiplex cytokine array were used to assay various cytokines

Inclusion Criteria:

• Patients with proliferative diabetic retinopathy who were scheduled for PPV for vitreous hemorrhage or tractional retinal detachment (TRD)

Exclusion Criteria:

• Eyes with any pharmacologic intervention on study eye within 6 months
• Eyes with panretinal photocoagulation on study eye within 3 months
• Eyes with any pharmacologic intervention on fellow eye within 3 months,
• History of ocular diseases other than diabetic retinopathy
• History of PPV on study eye
• History of systemic thromboembolic events including myocardial infarction and cerebrovascular accidents.